Cardiometabolic screening for people after early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a screening program to look for heart- and metabolism-related health risks in people who have completed treatment for early breast cancer. It may help catch problems earlier so you can get timely care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer (not metastatic)
- You finished your local and/or whole-body (systemic) treatment at least 3 months ago
- You currently receive breast cancer treatment care at Johns Hopkins or its clinic locations in Baltimore, Lutherville-Timonium, or Washington D.C.
- You can read and speak English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who are being screened and just diagnosed with breast cancer and haven’t started treatment yet. It may help researchers understand how to better manage care from the start of treatment.
This trial tests a self-management program to reduce heart disease risks in women who have had breast cancer. It might help you if you have a heart condition and have finished active cancer treatment.
This study looks at how your metabolism (things like blood sugar and cholesterol) might be linked to tumor genes and growth in people with breast cancer. The goal is to find new ways to treat the disease based on your metabolic profile. You may be eligible if you have locally advanced breast cancer (Stage II–III) and are willing to share your medical records.
This trial studies whether a structured exercise program can improve cardiovascular (heart and blood vessel) health in post-menopausal women after early-stage breast cancer treatment. It specifically targets women who have trouble with exercise and have completed cancer treatment within the last 1 to 5 years.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at how well your body uses insulin (a hormone that helps move sugar from the blood into cells) after breast cancer treatment. It may help researchers understand whether insulin sensitivity changes after chemotherapy and could guide future health monitoring.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.